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Evidence garnered from both human autopsy studies and ge-
netic animal models has suggested a potential role for astro-
cytes in the pathogenesis of amyotrophic lateral sclerosis
(ALS). Currently, mutations in the gene encoding Cu/Zn super-
oxide dismutase (SOD1) represent the only known cause of
motoneuron loss in the disease, producing 21q linked familial
ALS (FALS). To determine whether astrocytic dysfunction has a
primary role in familial ALS, we have generated multiple lines of
transgenic mice expressing G86R mutant SOD1 restricted to
astrocytes. In GFAP-m SOD1 mice, astrocytes exhibit signifi-
cant hypertrophy and increased GFAP reactivity as the animals
mature. However, GFAP-mutant SOD1 transgenic mice develop
normally and do not experience spontaneous motor deficits
with increasing age. Histological examination of spinal cord in
aged GFAP-mSOD1 mice reveals normal motoneuron and mi-
croglial morphology. These results indicate that 21q linked
FALS is not a primary disorder of astrocytes, and that expres-
sion of mutant SOD1 restricted to astrocytes is not sufficient to
cause motoneuron degeneration in vivo. Expression of mutant
SOD1 in other cell types, most likely neurons, is critical for the
initiation of disease.
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Amyotrophic lateral sclerosis (ALS) is characterized by the pro-
gressive loss of motoneurons, leading to profound weakness and
death of affected individuals. Because it is motoneurons that
invariably die in ALS, most attention has focused on these cells as
the primary site where pathophysiological injury is initiated.
However, evidence garnered from human autopsy studies and
genetic animal models has suggested a potential role for astro-
cytes in the pathogenesis of ALS. Abnormalities in astrocytic
function particularly related to glutamate transport have been
well documented in ALS patients. Astrocytes from the brains of
ALS patients manifest selective decreases in expression of full-
length and functional EAAT–2 protein, which serves as the
principle glutamate transporter in the CNS (Rothstein et al.,
1994, 1995, 1996). Recent investigations have shown that aberrant
processing of EAAT-2 mRNA transcripts occurs in ALS astro-
cytes and yields alternatively spliced forms of the protein that act
as dominant negative inhibitors of normal EAAT-2 expression
function (Lin et al., 1998). Such decreases in functional astroglial
EAAT-2 expression in vivo potentially explain the significant
reduction in glutamate transport function observed in synapto-
somes from ALS brains and, as well, the overall elevation in CSF
glutamate levels observed in ALS patients (Rothstein et al.,
1992). Together these findings have led to the formulation of a
hypothesis concerning ALS pathogenesis in which astrocyte dys-
function is critical (Bai and Lipton, 1998). However, partly be-
cause the pathogenesis of sporadic ALS is unknown, no model
system exists to test whether observed alterations in astrocytes
contribute significantly to the disease process.
Although the etiology of sporadic ALS is unknown, mutations
in the gene encoding Cu/Zn superoxide dismutase (SOD1) have
been found to cause one form of familial ALS (FALS) (Rosen et
al., 1993). The process by which mutant (m) SOD1 leads to
motoneuron degeneration remains unclear, but studies involving
the use of transgenic animals clearly point to a toxic gain of
function model for the abnormal protein. Mice with targeted
deletions of both SOD1 alleles do not develop spontaneous mo-
toneuron loss (Reaume et al., 1996). In contrast, transgenic mice
overexpressing mSOD1 develop spontaneous motoneuron degen-
eration and represent an excellent animal model of the disease
(Gurney et al., 1994; Ripps et al., 1995; Wong et al., 1995; Tu et
al., 1996).
Astrocytic alterations occur in mSOD1 transgenic mice. Patho-
logical examination of transgenic mice expressing a G85R
mSOD1 demonstrates abnormal protein inclusions in astrocytes
even at early clinically presymptomatic time points when mo-
toneuron pathology is not readily apparent (Bruijn et al., 1997).
In addition, these mice also exhibit selective loss of the principal
astrocytic glutamate transporter GLT-1 and manifest alterations
in glutamate transport function, mirroring those observed in
human disease (Bruijn et al., 1997; Canton et al., 1998). However,
experiments to date have been unable to delineate whether the
astrocyte abnormalities observed in mSOD1 transgenic mice rep-
resent primary dysfunction of this cell type or occur secondary to
neuronal injury, let alone determine whether these astrocytic
changes contribute to disease pathogenesis or represent
epiphenomena.
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Conventional lines of mSOD1 mice are problematic for under-
standing the role of astrocytes in the disease process. Because
these lines use the endogenous SOD1 promoter to drive trans-
gene expression, mSOD1 is expressed ubiquitously in all cells
including neurons and glia. Consequently, these animals are un-
suitable to determine which cell type is critical in initiating the
process leading to motoneuron loss. We therefore have generated
transgenic mice expressing mSOD1 under the control of an
astrocyte-specific promoter and asked whether such mice develop
spontaneous motoneuron degeneration and astrocytic pathology.
MATERIALS AND METHODS
Construct design and generation of GFAP-G86R transgenic mice. A cDNA
encoding full-length normal murine SOD1 was obtained using P1 mouse
brain RNA, reverse-transcribed with random primers (Superscript re-
verse transcriptase). An aliquot of this mixture was then used to amplify
normal murine SOD1 cDNA. Primers were used (5[prime- ACT AGT
ATG GCG ATG AAA GCG GTG-39 and 59-GGA TCC TGT TTA CTG
GGC AAT CCC-39) to amplify the full-length murine SOD1 with Spe1
and BamHI restriction sites on the 59 and 39 end, respectively. PCR
conditions were 94°C for 4 min, 94°C for 1 min, 60°C for 1 min, and 72°C
for 1.5 min for 35 cycles followed by a 7 min extension at 72°C. A band
corresponding to a 465 nucleotides was obtained and cloned directly into
a PCR II cloning vector (Invitrogen, San Diego, CA). After sequencing
to confirm normal SOD1 sequence, this plasmid was digested with SpeI
and BamHI and then cloned into pBluescript II(p-SOD2). This plasmid
was then used to generate G86R SOD1. For this amino acid substitution,
the base at position 256 must be changed from G to C. A reverse primer
incorporating this change was designed using sequence 250 to 294, which
also has BalI site at the 39 end (59-CAC ATT GGC CAC ACC GTC CTT
TCC AGC AGT CAC ATT GCG CAG GTC-39). This primer and the
original 59 SOD1 primer (listed above) were used to amplify a 295 bp
fragment, which was then cloned (p-BAL frag) and sequenced to confirm
the appropriate G to C change at 256. After a Spe1and BalI digestion, this
altered 295 bp SOD fragment was ligated into PSOD2, which had also
undergone SpeI and BalI digestion to then yield a full-length SOD1 with
a G to C change at 256 (p-BAL-SOD1). This plasmid was confirmed
again by sequencing. A 2.3 kb fragment (Brenner et al., 1994) containing
the 59 flanking DNA sequence derived from the human glial fibrillary
acidic protein (GFAP) gene was available in Bluescript SK II with
flanking SpeI sites. This GFAP promoter was excised with SpeI and
ligated into the SpeI site of p-BAL-SOD to generate p-GFAP-mSOD.
An 850 bp SV40 small t-antigen with an intron and polyadenylation
sequence was cloned into PGFAP-SOD using EcoRV and SalI sites to
generate p-GFAP-mSOD1-SV40, which was then excised with NotI and
SalI and used for pronuclear injection (strainB6/CBA). Integration of the
transgene into the mouse genome was determined by Southern blotting
and PCR on genomic DNA extracted from mouse tails.
Southern blot and PCR analysis. Ten micrograms of genomic DNA
isolated from mouse tail were digested with digested with BamHI and
KpnI, separated on a 0.8% agarose gel, and then transferred to a positive
charged nylon membrane (Boehringer Mannheim, Indianapolis, IN) via
overnight capillary transfer. A dig-dUTP 450 bp probe generated by PCR
(PCR-dig kit; Boehringer Mannheim), corresponding to full-length
SOD1 cDNA, was used for hybridization in DIG Easy Hyb solution
(Boehringer Mannheim) at 42°C. Hybridization of probe and DNA
fragment were visualized the using the DIG-Luminescent Kit (Boehr-
inger Mannheim) following the instructions of the manufacturer. Films
were be scanned and compared semiquantitatively between the differing
transgenic lines using NIH Image software (version 1.61). PCR analysis
(30 cycles: 94°C for 1 min, 64°C for 45 sec, and 72°C for 1 min 20 sec) was
performed for routine identification of mice carrying the transgene using
primers encompassing the 59 end of SOD1 and extending 150 bp into the
SV40 sequence.
In situ hybridization. In situ hybridization was performed following
methods previously described (Deckwerth et al., 1996; Parsadanian et al.,
1998). Animals were deeply anesthetized with sodium pentobarbital and
then decapitated. Spinal cord and brain were rapidly dissected out,
frozen on dry ice, and 12 mM sections were cut on a Zeiss micom cryostat.
Plasmid (p-SV40–1) containing the fragments encoding the 850 bp SV40
small t-antigen were linearized with appropriate restriction enzymes for
subsequent sense and antisense in vitro transcription The antisense probe
recognizes only transgene mRNA. cRNA probes were transcribed in vitro
using the appropriate RNA polymerase in the presence of 50 mCi
33P[UTP] (NEN). Hybridization occurred overnight at 55°C in the
presence of 1 3 10 6 cpm 33P[UTP] labeled riboprobe diluted in a
hybridization mixture. The following day slides were rinsed in 43 SSC,
at 37°C, followed by a 30 min wash in RNase A (20 mg/ml) at 45°C. Slides
were then rinsed at 37°C in 23 SSC, 0.53 SSC, and 0.13 SSC. Slides
were then exposed to Biomax film (Eastman Kodak, Rochester, NY) for
3–4 d to generate autoradiographs. Slides were dipped in Kodak NTB-2
emulsion and stored in light-tight boxes for 2 weeks, developed with
Kodak developer and fixer, and counterstained with hematoxylin and
eosin.
Western blotting. Animals were overdosed with sodium pentobarbital
(250 mg/kg, i.p.). Spinal cords were dissected, homogenized (in mM: 20
Tris–HCl, pH 7.5, 2 DTT, 1 EDTA, and 1 EGTA, with leupeptin 0.1
mg/ml), then centrifuged at 13,000 3 g with pelleted debris discarded.
Protein concentration was measured using the BCA protein assay
(Pierce, Rockford, IL). Five micrograms of protein from each sample was
loaded on a 14% Tris–glycine gel (Novex). A range of known concen-
trations of bovine SOD 1 (Sigma, St. Louis, MO) were loaded. Gel was
gently rinsed with transfer buffer (Tris base 12 mM, glycine 96 mM, and
20% methanol) and placed against a polyvinylidene difluoride mem-
brane. Transfer was performed at 25 V, 100 mA for 2 hr. Membranes
were washed in PBS followed by incubation in blocking solution [0.2%
I-block (Tropix), PBS, and 0.1% Tween 20] overnight at room temper-
ature. Membrane was incubated with primary antibody, a polyclonal
rabbit anti-bovine SOD1 (Chemicon, Temecula, CA) antibody, at 1:4000
dilution in blocking buffer for 1–2 hr. After washing, membrane was
incubated with a secondary anti-rabbit antibody-alkaline phosphatase
conjugate (Tropix) (1:5000 in blocking buffer) as well as with an
Avidix-AP streptavidin-alkaline phosphatase conjugate (1:20,000) for 1
hr. After washing, the membrane underwent a 5 min incubation with
CSPD chemoluminescent alkaline phosphatase substrate (Tropix). After
exposure to Kodak X-omat film, films were scanned and then imported
into NIH Image for quantitation of band density.
Stride test. This test was performed with modifications from Gurney et
al. (1994). Animals were trained to walk across a 1 m flat board. These
animals then had their hindpaws dipped with a nontoxic ink and were
allowed to walk across the 1 m board that had white construction paper
over the top for recording footprints. Stride lengths were measured in
millimeters. Statistics on data were be performed using Student’s t test.
All procedures performed on mice were approved by an animal research
committee and conform to National Institutes of Health guidelines.
Immunochemistry and histology. After overdose with pentobarbital,
animals were perfused with 4% paraformaldehyde and had spinal cords
and brains removed. For routine histology, tissue was embedded in
plastic, sectioned (1 mm), and stained with toluidine blue. For immuno-
histochemistry, paraffin-embedded sections (4 mm) were incubated with
a rabbit polyclonal GFAP antibody (Dako, Glostrup, Denmark) (1:200
dilution) and visualized using an immunoperoxidase reaction (the one
kit, Sternberger Monoclonals). For studies of morphology, four GFAP-
mSOD1 and three wild-type littermates were used for each time period
studied (4 and 12 months of age). Multiple sections from GFAP-mSOD1
and wild-type sibling lumbar spinal cords were processed and stained
simultaneously. Photomicrographs were taken, scanned, and then im-
ported into NIH Image version 1.61, where the area of GFAP-positive
astrocytes (in pixels) was obtained. At least 250 astrocytes from GFAP-
mSOD1 and wild-type littermates of 4 and 12 months of age were used
per age group. Measurements were performed by a single investigator
who was unaware of the animal genotype. To assess microglia, sections
were washed in TBS followed by overnight incubation with a tomato
(Lycopersicon esculentum) lectin (Sigma) conjugated to fluorescein (1:70
dilution). G93A conventional mSOD1 mice were obtained from The
Jackson Laboratory (Bar Harbor, ME).
RESULTS
Construct design and line analysis of GFAP-(m)SOD1
transgenic mice
To generate transgenic mice expressing G86R mSOD1 restricted
to astrocytes, we designed a construct that uses a 2.3 kb flanking
sequence 59 to the human GFAP gene (Brenner et al., 1994). This
promoter region has been shown to drive high levels of astrocyte-
specific expression in transgenic mice beginning at early postnatal
periods and extending into adulthood (Brenner et al., 1994;
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Raeber et al., 1997). This promoter fragment is also capable of
driving transgene upregulation in the setting of an injury, which
would typically result in increased GFAP protein synthesis, such
as occurs in conventional mutant SOD1 transgenic mice. We
selected the murine G86R SOD1 mutation (G85R in humans)
because earlier experiments had shown that expression of this
altered protein under the control of the endogenous SOD1 pro-
moter is capable of producing motoneuron disease in vivo with
both neuronal and astrocytic dysfunction (Ripps et al., 1995;
Bruijn et al., 1997). Figure 1a demonstrates the overall construct
design used for pronuclear injection and the generation of GFAP-
SOD1 transgenic mice.
After injection of the transgene construct, six founder mice
(5512–2, 5512–4, 5512–9, 5512–19, 5512–29, and 5512–31) were
identified by initial PCR screening. Relative transgene copy num-
ber was determined by Southern blot analysis after digestion of
genomic DNA with BamHI and HindIII (Fig. 1b). This digestion
yields a 729 bp fragment of the transgene that encompasses the
entire SOD1 cDNA and a 250 bp segment of the 39 end of the
GFAP promoter. Relative transgene copy number differed for
each line varying from line 5512–9 (1x) to line 5512–29 (10x).
Lines 5512–29 and 5512–2 demonstrated the highest number of
transgene copies and were used for further analysis of transgene
transcription and translation. Line 5512–19 exhibited a rearrange-
ment of the transgene, and although still bred, was not used for
further experiments.
To assess whether transgene incorporation resulted in in-
creased protein production, we performed Western blot analysis
on spinal cords from lines 5512–29 and 5512–2 (Fig. 1c). Available
antibodies against SOD1 were not capable of distinguishing be-
tween normal and mutant murine SOD1, so total SOD1 protein
levels were assayed. Initial blots performed on tissue from
6-week-old animals revealed significantly increased levels of total
SOD1 protein expression in spinal cords from transgenic GFAP-
mSOD1 transgenic mice as compared to wild-type controls. Cor-
relating with copy number, line 5512–29 demonstrated higher
total SOD1 expression than did line 5512–2. Increased total
SOD1 expression in spinal cord was also observed in older trans-
genic GFAP-mSOD1 mice up to 5 months of age (the oldest age
examined). We next used in situ hybridization to test whether
expression of the mutant SOD1 was in fact restricted to astrocytes
(Fig. 2). By generating a riboprobe complimentary to the SV40
t-antigen, we were able to distinguish the cells that were tran-
scribing the transgene. In situ hybridization demonstrated robust
transgene synthesis in both white and gray matter portions of
spinal cord from line 5512–29. High-power bright-field micros-
copy revealed that expression of transgene was limited to glial
Figure 1. a, Schematic representation of construct used in generation of
GFAP-mSOD1 mice. The C for G substitution in the first base at codon
86 causes a glycine to arginine change. b, Southern blot analysis of
GFAP-mSOD1 transgenic lines. BamHI and KpnI digestion of DNA
yields a 729 bp fragment in transgenic mice. Con, p-GFAP-mSOD1-SV40;
WT, wild-type. c, Western blot analysis of SOD1 in spinal cords from
adult GFAP-mSOD1 and wild-type mice using rabbit anti-bovine SOD1.
Lanes 1, 2, Wild-type (WT ) mouse; 2.5 mg and 5 mg of total protein
loaded, respectively. Lanes 3, 4, Line 5512–2; 2.5 mg and 5 mg of total
protein loaded. Lanes 5, 6, Line 5512–29; 5 mg and 2.5 mg of total protein
loaded. Lane 7, Bovine SOD1 control; 0.02 mg of protein loaded.
Figure 2. Expression of mSOD1 transgene is restricted to non-neuronal
cells in the spinal cord. a , b, Transverse sections of spinal cord from
6-week-old wild-type (a) and line 5512–29 GFAP-mSOD1 (b) mice
hybridized with antisense riboprobe for the SV40 sequence, which detects
only transgene expression. Dark-field microscopy, Magnification, 403. c,
d, Bright-field views of wild-type (c) and GFAP-mSOD1 ( d) ventral horn.
Arrowheads indicate neuronal cell bodies. Silver grains are observed only
over glial cells in GFAP-mSOD1 mice (arrows). Magnification, 4003.
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cells and not neurons. Similar findings were observed in brain-
stem sections from 5512–29 mice. GFAP-mSOD1 mice from line
5512–2 also expressed transgene message limited to glial cells in
spinal cord and brainstem, but again correlating with total copy
number and results from Western blotting, line 5512–2 exhibited
overall less robust transgene expression than did 5512–29.
GFAP-SOD1 survival and motor function
All six GFAP-mSOD1 transgenic founders were bred and fol-
lowed longitudinally for signs of motor dysfunction as well as for
survival analysis. GFAP-mSOD1 mice exhibited normal early
development, reproductive capacity, and survival curves compa-
rable to wild-type mice at least until 16 months of age (the oldest
age yet attained). Founder 5512–2 did die suddenly at 4 months of
age. However, this founder demonstrated no signs of motor
dysfunction before death, and its transgenic offspring are alive at
1 year of age. Even up to 16 months of age, GFAP-mSOD1 mice
do not display abnormalities in gross motor function or postural
reflexes. The stride length test was used to assess motor function
quantitatively, in a method that had been used to test motor
function in conventional mutant SOD1 mice (Fig. 3). Compared
to wild-type littermates, GFAP-mSOD1 mice exhibited an iden-
tical pattern of stride length distance beginning at 1 month of age
and continuing until past 1 year of age. Thus, at least for the first
16 months of life, GFAP-mSOD1 mice do not appear to develop
clinical signs of motor neuron dysfunction.
Neuronal and glial morphology in GFAP-mSOD1
transgenic mice
We performed histological and immunhistochemical analysis on
1-year-old GFAP-mSOD1 mice from line 5512–29 to determine
whether these mice developed any pathological evidence of neu-
ronal or glial dysfunction. Thin plastic sections of spinal cord
ventral horn demonstrated normal motoneuron morphology with-
out evidence of cytoplasmic vacuoles (Fig. 4). Imunnohistochemi-
cal analysis with antibodies directed against phosphorylated neu-
rofilaments or ubiquitin in GFAP-mSOD1 mouse tissue did not
reveal any neuronal inclusions in spinal cord motor neurons that
are characteristic of affected neurons in conventional mSOD1
mice (data not shown).
We next asked whether glia manifested any morphological or
biochemical abnormalities. Immunostaining spinal cord from
GFAP-mSOD1 demonstrated increased GFAP reactivity as com-
pared to wild-type age-matched littermates (Fig. 5). In addition,
astrocytic morphology had changed from fine stellate-appearing
cells in wild-type animals to a larger and more globular appear-
ance in GFAP-mSOD1 mice. GFAP-immunoreactive spinal cord
astrocytes were significantly larger in GFAP-mSOD1 mice com-
pared to age-matched wild-type controls [mean area (pixels) 6
SEM: WT, 147 6 8; GFAP-mSOD1, 225 6 8; p , 0.001].
However, changes in both GFAP reactivity and astrocytic hyper-
trophy in GFAP-mSOD1 mice were not as extensive as those
observed in endstage conventional mutant SOD1 transgenic mice
with a mean area of 392 6 29 pixels for astrocytes. Interestingly,
changes in astrocytic morphology were not observed in the ven-
tral horn of younger GFAP-mSOD1 mice. At 4 months of age,
there was no difference in size between spinal cord astrocytes in
wild-type (138 6 5 pixels) and GFAP-mSOD1 mice (143 6 9
pixels). This finding indicates that the astrocytosis in GFAP-
mSOD1 mice is not present at younger ages but develops as the
animals mature.
To assess changes in microglia we used a lectin (L. esculentum)
that binds poly N-acetyl lactosamine residues in both activated
and nonactivated microglia (Acarin et al., 1994). Both wild-type
and GFAP-mSOD1 mice exhibit rare microglia in spinal cord in
contrast with the markedly increased number of microglia present
in conventional mutant SOD1 mouse spinal cord (data not
shown). These results indicate that if mutant SOD1 expression is
astrocyte specific, than pathological changes appear restricted to
this cell type and do not promote subsequent neuronal dysfunc-
tion or microglial proliferation.
DISCUSSION
Although previous studies have described abnormalities in astro-
cytes in both autopsied human ALS tissue as well as in transgenic
mouse models of FALS, they have not adequately addressed the
issue of whether primary astrocytic dysfunction is capable of
causing motoneuron degeneration in ALS. Mutant SOD1 expres-
sion in vivo provides a model system to test whether astrocytic
changes induced by mSOD1 are critical in the pathogenesis of
ALS. Here we demonstrate that mutant SOD1 expression limited
to astrocytes results in significant changes to this cell type in
transgenic mice but is not sufficient to cause motoneuron death or
motor dysfunction in vivo. Although it is possible that with even
higher levels of mSOD1 production in astrocytes, we may have
observed motoneuron loss, we feel that this occurrence is unlikely
Figure 3. Stride length in GFAP-mSOD1 transgenic female mice from
line 5512–29 and wild-type littermates. There is no significant difference
in stride length between the two groups. n 5 4 for each group.
Figure 4. Toluidine-stained plastic sections of the ventral horn from
1-year-old wild-type (a, c) and line 5512–29 GFAP-mSOD1 mice (b, d).
Arrows indicate motoneurons. Magnification, 2003 for a and b; 6003 for
c and d.
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for a number of reasons. First, in conventional mSOD1 transgenic
mice, expression of even small amounts of G85R SOD1, repre-
senting a fraction of total SOD1 protein produced, is sufficient to
cause disease with a time course resulting in death by ;12–14
months of age (Bruijn et al., 1997). In addition, our in situ
hybridization experiments demonstrate that robust transgene
transcription in our highest expressing lines of GFAP-mSOD1
mice is widely distributed, occurring not only in glial cells sur-
rounding motoneurons in the ventral horn but also in glia
throughout the spinal cord and into white matter tracts. Third,
the morphological changes we have observed in GFAP-mSOD1
astrocytes also would offer support of transgene expression at
levels capable of altering basic astrocytic properties.
Recently, Trotti et al. (1999) have demonstrated that mSOD1
selectively inactivates the GLT-1 transporter in vitro when both
proteins are expressed in Xenopus oocytes and propose that this
finding accounts for the toxic properties of mSOD1 leading to
motoneuron degeneration. Their experiments and conclusion
again imply a principal and critical role for astrocytes in initiation
of the disease process. However, our results indicate that 21q
linked FALS is not a primary disease of astrocytes as might be
predicted by the glutamate hypothesis, but that expression of
mutant SOD1 in another cell type is critical for manifestations of
disease. It is likely, although not proven, that neuronal expression
of mutant SOD1 is necessary for the disease process and that
mutant SOD1 would likely exert its toxic effects directly on
motoneurons. Although precise mechanisms of mutant SOD1
toxicity within neurons are unclear, several possibilities including
enhanced generation of hydroxyl radicals or increased peroxyni-
trite formation by the mutant enzyme have been suggested by a
number of investigations (Beal et al., 1997; Crow et al., 1997;
Ferrante et al., 1997; Bogdanov et al., 1998; Pedersen et al., 1998).
Our results do not exclude the possibility that astrocytes may
contribute to progression of FALS after the disease process has
been initiated in another cell type. Neurons appear capable of
regulating expression of astrocytic proteins possibly via the se-
cretion of diffusable factors as has been demonstrated for gluta-
mate transporter subtypes (Swanson et al., 1997). Primary neu-
ronal dysfunction could trigger inappropriate and harmful
astrocytic responses that potentiate neuronal injury or allow its
propagation, including release of cytokines or alterations in glu-
tamate transporter expression (Campbell et al., 1993; Chavany et
al., 1998).
Although GFAP-mSOD1 mice do not develop motor dysfunc-
tion or motoneuron pathology, astrocytes in these animals do
undergo changes, including hypertrophy and increased GFAP
expression. Because such changes occur in GFAP-mSOD1 mice
in whom motoneuron pathology does not occur, this indicates
that mSOD1 expression in astrocytes alone is sufficient to cause at
least some degree of astrocytosis that is not reactive but primary.
The fact that the astrocytosis in GFAP-mSOD1 develops as the
mice mature and is not present in younger adult mice suggests
that there is a gradual accumulation of potentially noxious factors
within astrocytes leading to injury but not degeneration.
It is interesting to note that pronounced alterations in astro-
cytic morphology have been observed in conventional mutant
SOD1 transgenic mice that develop weakness. Remarkably, these
changes can be observed in astrocytes located not only in close
proximity to motor neuron populations (i.e., ventral horn) but
also in astrocytes at a distance from motor pools such as in the
dorsal horn or rostral pons. One possible explanation for this
phenomenon is that mutant SOD1 exerts its toxic effects on many
differing populations of neurons extending beyond motor neuron
pools and that astrocytes throughout the CNS then undergo
Figure 5. Astrocyte morphology in the
ventral horns of 1-year-old wild-type
(A), 1-year-old GFAP-mSOD1 (B), and
8-month-old (endstage) G93A SOD1
(C) mice identified by GFAP immuno-
reactivity. Magnification, 4003. D,
Area of ventral horn GFAP-reactive
cells from 1-year-old WT and 5512–29
mice as well as endstage (8 month)
G93A SOD1 mice. *p , 0.0001 versus
wild-type.
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changes secondary to this diffuse neuronal injury (Dal Canto and
Gurney, 1994; Kliveny et al., 1999). However, our experiment
would suggest that mSOD1 expression directly within astrocytes
is capable of altering astroglial morphology. Together, these
results suggest that the astrocytosis in conventional mSOD1 mice
is derived from a combination of both secondary astrocytic reac-
tion to neuronal dysfunction as well as primary direct astrocytic
dysfunction.
Although this study demonstrates that mutant SOD1-induced
disease is not a primary disease of astrocytes, 21q linked FALS is
responsible for only ;20% of familial cases and ,5% of all ALS
cases. It is unclear whether the conclusions reached from studying
a transgenic murine model of FALS can be broadened to include
the sporadic form of disease, despite common pathological and
biochemical features that have been observed both in the animal
model and human disease.
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